Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials -- Ignore unavailable to you. Want to Upgrade?

To: Janice Shell who wrote (183)	1/20/2003 11:53:38 PM
From: scion	Read Replies (1) \| Respond to of 250

VaxGen: Agreement for VaxGen to develop gp120, a potential prophylactic AIDS vaccine. GENENTECH Genentech's partnering goals are to access novel products and technologies that strengthen our internal research and development pipeline; and to provide vehicles to develop Genentech's late-stage research products that require additional development resources. Strategic Alliances Some of Genentech's collaborations include: Abgenix, Inc.: Research license that allows Genentech to use Abgenix's XenoMouse™ technology to develop fully human monoclonal antibodies. Actelion: Collaboration to develop and co-promote Actelion's parenteral endothelin receptor antagonist (tezosentan) for the treatment of acute heart failure in the United States and a separate collaboration for the development and co-promotion of Actelion's oral endothelin receptor antagonist Tracleer™ (Bosentan) in the United States for pulmonary hypertension (PHT) and chronic heart failure (CHF). Alkermes: Collaboration to develop Nutropin Depot® [somatropin (rDNA origin) for injectable suspension], a sustained-release formulation of Genentech's human growth hormone based on Alkermes' ProLease drug delivery system. Amgen: Collaboration to develop and commercialize TRAIL/Apo2L for cancer. Aurora Biosystems: License agreement for use of Green Fluorescent Protein (GFP) technology for genomics and manufacturing of therapeutic proteins Aventis SA: Collaboration to develop small molecule vitronectin receptor antagonists for treatment of chronic bone disorders. Boehringer Ingelheim: Collaboration to develop and market Activase® (Alteplase, recombinant) and TNKase™ (Tenecteplase) outside the U.S. and Canada. Cambridge Antibody Technology: Collaborative research agreement based on CAT antibody engineering technology. Connetics: Agreement to develop relaxin for the treatment of connective tissue disorders and other indications. COR Therapeutics & Schering-Plough: Collaboration to co-promote INTEGRILIN for non-ST-segment acute coronary syndromes (ACS), as well as TNKase and Activase for acute ST-segment elevation myocardial infarction in hospitals across the United States. CuraGen Corporation: Genentech and CuraGen are using CuraGen's GeneCalling® and PathCalling® genomics systems and other technologies to identify leads for a range of novel therapeutics based on functional genomic drug discovery tools. DAKO: Agreement for DAKO to develop and commercialize an in vitro diagnostic kit to be used to screen breast cancer patients for overexpression of HER2. Genetics Institute: Agreement to provide Genentech with access to the DiscoverEase® library of secreted proteins. IDEC: Collaboration to develop and copromote Rituxan® (Rituximab) for the treatment of non-Hodgkin's lymphoma. ImmunoGen: License to ImmunoGen's maytansinoid Tumor Activated Prodrug (TAP) technology for use with antibodies such as Herceptin® (Trastuzumab). Incyte: Access to Incyte's LifeSeq® DNA sequence and gene expression database. Extended in 1999. Intermune: License to market Actimmune® in the U.S. for the management of chronic granulomatous disease and other infectious diseases. Millennium: Partnership to develop and commercialize Millennium's LDP-02, a humanized monoclonal antibody for the treatment of inflammatory bowel disease. Novartis & Tanox: Collaboration to develop and commercialize anti-IgE monoclonal antibodies for allergic asthma and seasonal allergies. OSI Pharmaceuticals & Roche: Concurrent agreements for the global co-development and commercialization of OSI's lead anti-cancer drug, Tarceva™ (erlotinib), an inhibitor of the epidermal growth factor receptor (EGFR) for a wide range of solid tumors. Pharmacia & Upjohn: Collaboration to develop and commercialize Genentech's thrombopoietin (TPO) for treating patients with complications from cancer chemotherapy. Roche: Collaborations to develop and market Herceptin and Rituxan products outside the U.S. and to market Pulmozyme® (dornase alfa), Activase, TNKase and growth hormone in Canada. Seattle Genetics: License agreement to develop anti-CD40 and other anti-cancer agents. Sensus Corporation: Agreement for Sensus to develop growth hormone antagonists for treating certain growth disorders. Sumitomo Pharmaceuticals Corp.: Collaboration to distribute Genentech's human growth hormone product, Nutropin AQ™, in Japan. Urogenesys: License to develop antibody-based therapeutics for cancer using UroGenesys' Prostate Stem Cell antigen (PCSA) as a target antigen. VaxGen: Agreement for VaxGen to develop gp120, a potential prophylactic AIDS vaccine. XOMA: Collaboration to develop Genentech's anti-CD11a monoclonal antibody for psoriasis and other indications. Product Listing Delivering innovative medicines to patients with serious or life-threatening medical conditions is what Genentech is all about. Since its beginning in 1976, the company has focused its drug discovery efforts on therapies that would fill unmet needs. Today, Genentech manufactures and commercializes 11 protein-based biotherapeutics for serious or life-threatening medical conditions -- giving Genentech one of the leading product portfolios in the biotech industry. Oncology Herceptin® (Trastuzumab) Anti-HER2 antibody For metastatic breast cancer in HER2 overexpressed tumors Rituxan® (Rituximab) Anti-CD20 antibody For relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma Thrombolytics Activase® (Alteplase, recombinant) A tissue-plasminogen activator For acute myocardial infarction, acute ischemic stroke and acute massive pulmonary embolism Cathflo® Activase® (Alteplase) Thrombolytic agent For the restoration of function to central venous access devices as assessed by the ability to withdraw blood TNKase™ (Tenecteplase) Single-bolus thrombolytic agent For the treatment of acute myocardial infarction (AMI) Other Unmet Needs Nutropin Depot® [somatropin (rDNA origin) for injectable suspension] Growth hormone For growth hormone deficiency (GHD) in children Nutropin AQ® [somatropin (rDNA origin) injection] Liquid formulation growth hormone For GHD in children and adults; growth failure associated with chronic renal insufficiency (CRI) prior to kidney transplantation; short stature associated with Turner syndrome Nutropin AQ Pen™ for use with Nutropin AQ Pen™ Cartridge [somatropin (rDNA origin) injection] Liquid formulation growth hormone For GHD in children and adults; growth failure associated with chronic renal insufficiency (CRI) prior to kidney transplantation; short stature associated with Turner syndrome Nutropin® [somatropin (rDNA origin) for injection] Growth hormone For GHD in children and adults; growth failure associated with CRI prior to kidney transplantation; short stature associated with Turner syndrome Protropin® (somatrem for injection) Growth hormone For growth hormone deficiency (GHD) in children Pulmozyme® (dornase alfa) Inhalation Solution For management of cystic fibrosis (including patients under age 5) gene.com